HRT and hormone treatments for women, backed by bloodwork.

HRT (hormone replacement therapy) replaces the estrogen, progestogen, and sometimes testosterone your body stops producing during the menopause transition. The terms get blurred in the market, so here’s how we use them.

Bioidentical means molecularly identical to the hormones your body makes. Bioidentical progestogen and transdermal estrogen are both prescription, pharmacy-dispensed, and what your specialist prescribes here.

“Natural” alternatives usually means OTC creams, compounded blends without quality oversight, or supplements marketed as hormonal support. They’re not regulated as drugs, the doses aren’t verified, and they don’t replace what’s actually missing.

Gambit prescribes Health Canada-approved bioidentical formulations, dispensed by licensed pharmacies, dosed against your bloodwork.

HRT is for women in perimenopause or menopause whose symptoms — hot flashes, night sweats, sleep disruption, brain fog, mood shifts, low libido, vaginal dryness, joint pain — are affecting how they live, and whose bloodwork supports a hormonal cause.

It’s generally not appropriate for women with a personal history of estrogen-sensitive cancer, active or prior blood clots, undiagnosed vaginal bleeding, severe liver disease, or who are pregnant or trying to conceive. Family history of breast cancer, cardiovascular disease, or migraines doesn’t automatically rule you out — it’s something the specialist factors into the protocol.

Your full medical history is reviewed before anything is prescribed.

No. Perimenopause counts. Symptoms often start in the early-to-mid 40s, sometimes earlier, before menstruation stops. If your bloodwork and symptoms point to declining ovarian hormone production, you qualify for evaluation regardless of whether your cycles have ended.

Current clinical guidance is also clear that hormone therapy is broadly favourable when started within roughly 10 years of the menopause transition. Earlier is generally better, not worse.

The eligibility panel checks a few key hormone markers to confirm whether your levels are low enough to qualify for treatment.

The comprehensive panel adds a multi-system view — estrogen markers, progestogen markers, androgen markers (including SHBG and free + total testosterone), adrenal markers, thyroid markers, fasting metabolic markers, lipids, liver enzymes, and inflammatory markers.

You see your numbers against age-appropriate female reference ranges. Your Gambit specialist uses them to decide whether HRT is indicated, what protocol fits, and how to monitor it.

This is the question every informed woman asks, and it deserves a careful answer.

The early-2000s combined-HRT studies that drove most of the breast-cancer fear used synthetic progestin formulations — a class of lab-made hormones not chemically identical to what the body produces. Subsequent research has shown that bioidentical progestogen formulations have a different, more favourable risk profile in this area. The route matters too: transdermal estrogen carries a different cardiovascular and clotting profile than oral estrogen and is generally the safer route for most patients.

Modern HRT, when prescribed against bloodwork and matched to personal and family history, looks very different from the regimens those headlines were built on. The specialist evaluates breast cancer history, family history, BRCA status if relevant, and recent screening before prescribing — and continues monitoring through bloodwork while you’re on therapy.

What HRT will not do is guarantee an outcome. What it will do is give you a clinically defensible decision based on your data, not a generic guideline written for someone else.

Women produce testosterone too — it drives energy, libido, mood stability, cognitive sharpness, and lean muscle. Levels decline through the 30s and 40s, often before estrogen does, which is why some women feel “off” years before classic menopause symptoms show up.

The version prescribed here is a low-dose compounded transdermal cream, dosed at female-physiologic levels — roughly 60 to 100 times lower than a male testosterone protocol. At this dose, it targets energy, libido, and cognition. It is not a muscle-building protocol and does not produce masculinizing effects when dosed correctly and monitored.

It’s prescribed off-label in Canada because no female-specific testosterone product is Health Canada-approved. Your specialist tracks total and free testosterone, SHBG, and other markers throughout treatment to keep your levels in range.

Vasomotor symptoms — hot flashes, night sweats — often start to ease within 2 to 4 weeks. Sleep, mood, and energy typically take 4 to 8 weeks. Cognitive clarity and libido changes can take 8 to 12 weeks of consistent use.

Bone-density and other long-term markers play out over months to years and are tracked through repeat bloodwork.

If you’re not seeing meaningful change at the expected window, your Gambit specialist reviews and adjusts the protocol — dose, route, and combination can all be tuned.

HRT is not a weight-loss therapy and is not prescribed for weight management. The honest answer is that most women on appropriate HRT see weight stay roughly stable.

What often shifts is the surrounding picture: better sleep, steadier mood, more energy, fewer cravings driven by hormonal swings. Those changes can make the lifestyle work that supports weight more sustainable. The hormone itself is doing the symptom work, not the scale work.

There’s no fixed end date for most patients. Modern guidance has moved away from hard time limits and toward periodic re-evaluation with the specialist.

Some women stay on HRT long-term because the benefits — symptom control, bone protection, quality of life — continue to outweigh the considerations. Others taper after symptoms resolve. Dose and route are also adjusted over time as your hormonal landscape shifts.

The decision is shared, ongoing, and based on your bloodwork, your symptoms, and your goals — not a calendar.

Hormone therapy is a specialist area. Most family doctors do excellent generalist care, but menopausal hormone management — bloodwork interpretation, formulation choice, route selection, ongoing titration — sits outside the scope of routine general practice. Many GPs refer these conversations onward for that reason.

Gambit’s specialist consultation is designed to complement your GP relationship, not replace it. We run the full panel, review symptoms and history together, and build a protocol you and your GP can both see. If your symptoms are real and a panel supports it, you have a defensible path forward — with documentation that travels back to your primary care record if you want it to.